骨粗鬆症治療の世界市場レポート 2025年

骨粗鬆症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.1％で178億4,000万米ドルに成長します。予測期間の成長は、座りがちなライフスタイルの増加、二次性骨粗鬆症の有病率の上昇、仮想骨折クリニック、骨粗鬆症の遺伝子治療、男性の骨の健康への注目の高まりなどに起因すると考えられます。予測期間における主な動向は、生物製剤の進歩、人工知能の統合、骨健康記録におけるブロックチェーン、機械学習の統合などです。

骨粗鬆症の有病率と発症率の上昇は、今後の骨粗鬆症治療市場の成長を促進すると予測されます。骨粗鬆症は、骨の強度や組成に変化がある場合、または骨量やミネラル密度が低下する場合に発生する骨の病気です。ほとんどの骨粗鬆症治療薬は、骨の劣化を遅らせることで効果を発揮するが、エストロゲンなどのホルモンベースの治療は、特に閉経直後に開始すると骨密度を維持するのに役立ちます。例えば、2022年5月、米国のバイオ医薬品会社であるアムジェンは、骨粗鬆症に関連した骨折の年間件数が68％増加し、2040年には320万件に達すると予測しました。さらに2022年4月、国立医学図書館は、英国では年間約54万9000件の脆弱性骨折が新たに記録され、その3分の1が男性に発生していると報告しました。高齢化により、この数字は2030年までに19.6％増加すると予想されています。その結果、骨粗鬆症の有病率と発生率の増加が骨粗鬆症治療市場の拡大に拍車をかけています。

骨粗鬆症治療市場の成長の原動力となっているのは、ヘルスケア支出の増加です。ヘルスケア支出とは、特定の期間内にヘルスケアサービスや製品に費やされる総支出のことです。骨粗鬆症治療は、診断検査、投薬、リハビリテーションサービス、潜在的な手術などの費用をカバーし、ヘルスケア費用の増加に大きく貢献しています。2022年11月、CIHIはカナダの総医療費が2021年の3,280億米ドルから2022年には3,310億米ドルへと0.8％増加すると予測しており、医療費の急増によって市場が拡大することを裏付けています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界骨粗鬆症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の骨粗鬆症治療市場：成長率分析
• 世界の骨粗鬆症治療市場の実績：規模と成長, 2019-2024
• 世界の骨粗鬆症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界骨粗鬆症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の骨粗鬆症治療市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビスフォスフォネート
• カルシトニン
• ホルモン療法
• 選択的エストロゲン受容体モジュレーター（SERM）
• 副甲状腺ホルモン関連タンパク質（PTHrP）類似体
• ランクリガンド（RANKL）阻害剤
• 世界の骨粗鬆症治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射可能
• その他のルート
• 世界の骨粗鬆症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 小売薬局および店舗
• オンライン薬局
• 世界の骨粗鬆症治療市場ビスフォスフォネートの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アレンドロネート
• リセドロネート
• イバンドロネート
• ゾレドロン酸
• 世界の骨粗鬆症治療市場カルシトニンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• サーモンカルシトニン
• 合成カルシトニン製剤
• 世界の骨粗鬆症治療市場ホルモン療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• エストロゲン補充療法
• 併用ホルモン療法（エストロゲンとプロゲステロン）
• 世界の骨粗鬆症治療市場選択的エストロゲン受容体モジュレーター（SERM）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ラロキシフェン
• バゼドキシフェン
• 世界の骨粗鬆症治療市場、副甲状腺ホルモン関連タンパク質（PTHrP）類似体のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PTHアナログ（テリパラチド）
• その他のPTHrP類似体
• 世界の骨粗鬆症治療市場RANKL阻害薬のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• デノスマブ

第7章 地域別・国別分析

• 世界の骨粗鬆症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の骨粗鬆症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 骨粗鬆症治療市場：競合情勢
• 骨粗鬆症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck and Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline Pharmaceutical Ltd.
• Takeda Pharmaceutical Company
• Eli Lilly and Company
• Amgen Inc.
• Novo Nordisk A/S
• Asahi Kasei Corporation
• AstraZeneca Plc.
• Viatris Inc.
• Teva Pharmaceuticals Industries Ltd.
• Daiichi Sankyo Company Ltd
• Dr. Reddy's Laboratories
• Gedeon Richter Plc.
• Celltrion Inc.
• Luye Pharma Group
• Ligand Pharmaceuticals Incorporated

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 骨粗鬆症治療市場2029：新たな機会を提供する国
• 骨粗鬆症治療市場2029：新たな機会を提供するセグメント
• 骨粗鬆症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Osteoporosis treatment encompasses medical interventions designed to manage and improve the condition of osteoporosis. This bone disease occurs when there is a decline in bone mass and mineral density, or when the composition and strength of bones change. The primary goals of osteoporosis treatment are to stop bone deterioration, reduce the risk of fractures, and enhance overall bone health.

Key pharmaceuticals involved in osteoporosis treatment include bisphosphonates, calcitonin, hormone therapy, selective estrogen receptor modulators (SERMs), parathyroid hormone-related protein (PTHrP) analog, and rank ligand (RANKL) inhibitor. Bisphosphonates, recognized for their efficacy in relieving bone discomfort associated with certain cancers and hypercalcemia, are pivotal in preventing osteoporotic fractures. These medications can be administered orally, through injections, and other modalities, with distribution channels spanning hospitals, retail pharmacies, stores, and online pharmacies.

The osteoporosis treatment research report is one of a series of new reports from The Business Research Company that provides osteoporosis treatment market statistics, including the osteoporosis treatment industry's global market size, regional shares, competitors with osteoporosis treatment market share, detailed osteoporosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the osteoporosis treatment industry. This osteoporosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The osteoporosis treatment market size has grown steadily in recent years. It will grow from $13.96 billion in 2024 to $14.62 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to aging population demographics, hormone replacement therapies, calcium and vitamin d supplementation, increased diagnostic tools, integration of digital health solutions

The osteoporosis treatment market size is expected to see strong growth in the next few years. It will grow to $17.84 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to rise in sedentary lifestyles, rising prevalence of secondary osteoporosis, virtual bone fracture clinics, gene therapy for osteoporosis, increased focus on men's bone health. Major trends in the forecast period include advancements in biologics, integration of artificial intelligence, blockchain in bone health records, integration of machine learning.

The rising prevalence and incidence of osteoporosis are anticipated to drive the growth of the osteoporosis treatment market in the future. Osteoporosis is a bone disease that occurs when there are changes in bone strength and composition, or when there is a decline in bone mass and mineral density. Most osteoporosis medications work by slowing the deterioration of bones, while hormone-based treatments, such as estrogen, can help maintain bone density, particularly when started shortly after menopause. For example, in May 2022, Amgen, a US-based biopharmaceutical company, projected that the annual number of osteoporosis-related fractures could rise by 68%, reaching 3.2 million by 2040. Additionally, in April 2022, the National Library of Medicine reported that approximately 549,000 new fragility fractures are recorded annually in the UK, with one-third of these cases occurring in men. Due to the aging population, this figure is expected to increase by 19.6% by 2030. Consequently, the growing prevalence and incidence of osteoporosis are fueling the expansion of the osteoporosis treatment market.

The growth of the osteoporosis treatment market is fueled by the escalating healthcare expenditures. Healthcare expenditures encompass the total spending on healthcare services and products within a specific timeframe. Osteoporosis treatment contributes significantly to the rising healthcare costs, covering expenses for diagnostic tests, medications, rehabilitation services, and potential surgeries. In November 2022, the CIHI projected a 0.8% increase in total health spending in Canada, from $328 billion in 2021 to $331 billion in 2022, underscoring the market's expansion facilitated by the surge in healthcare expenditures.

Major companies in the osteoporosis treatment market are concentrating on the development of advanced injectable therapies to maintain their competitive edge. Injectable osteoporosis treatments are administered through injections to help prevent bone loss and lower fracture risk in individuals with osteoporosis. These treatments provide a direct approach to improving bone density and enhancing skeletal health. For example, in November 2023, Apotex Corp., a Canada-based pharmaceutical company, introduced Teriparatide Injection. This pre-filled pen is designed for single-patient use in the treatment of osteoporosis, featuring a concentration of 250 mcg/mL and offering 28 daily doses of 20 mcg each per pen. This product aims to improve access to affordable treatment for approximately 10 million Americans affected by osteoporosis. Its development highlights Apotex's commitment to producing complex generic medications, ensuring that patients have access to high-quality treatment.

Leading companies in the osteoporosis treatment market are strategically focusing on the development of derivative capsules, particularly those containing vitamin D3, to attain a competitive advantage. In December 2022, Chugai Pharmaceutical Co., Ltd., based in Tokyo, collaborated with Towa Pharmaceutical, a Japan-based counterpart, to launch 'Edirol Tablets 0.5 µg/0.75 µg.' These capsules, featuring an active vitamin D3 derivative, are tailored for the treatment of osteoporosis. Specifically designed to enhance bone and calcium metabolism, Edirol Tablets aim to reduce vertebral fractures and increase bone mineral density, exemplifying the companies' commitment to cutting-edge solutions.

In May 2023, Abiogen Pharma, an Italy-based specialist in osteoarticular and bone metabolism diseases, acquired a 97.09% stake in EffRx Pharmaceuticals. This strategic acquisition, conducted for an undisclosed amount, serves to strengthen Abiogen Pharma's global presence and underscores its dedication to bone health and rare diseases. EffRx Pharmaceuticals, headquartered in Switzerland, possesses a portfolio that includes products for the treatment of postmenopausal osteoporosis, aligning with Abiogen Pharma's broader objectives in the field.

Major companies operating in the osteoporosis treatment market include Pfizer Inc., F. Hoffmann La Roche Ltd., Merck and Co Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline Pharmaceutical Ltd., Takeda Pharmaceutical Company, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Corporation, AstraZeneca Plc., Viatris Inc., Teva Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Ltd, Dr. Reddy's Laboratories, Gedeon Richter Plc., Celltrion Inc., Luye Pharma Group, Ligand Pharmaceuticals Incorporated, Radius Health Inc., Haoma Medica Ltd., EffRx Pharmaceuticals SA

North America was the largest region in the osteoporosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the osteoporosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the osteoporosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osteoporosis treatment market consists of revenues earned by entities by providing osteoporosis services such as physical therapy and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteoporosis treatment market also includes sales of alendronate, risedronate, Ibandronate, and zoledronic acid. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osteoporosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osteoporosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for osteoporosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osteoporosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Bisphosphonates; Calcitonin; Hormone Therapy; Selective Estrogen Receptor Modulators (SERMs); Parathyroid Hormone-Related Protein (PTHrP) Analog; Rank Ligand (RANKL) Inhibitor
• 2) By Route Of Administration: Oral; Injectable; Other Routes
• 3) By Distribution Channel: Hospitals; Retail Pharmacies And Stores; Online Pharmacies
• Subsegments:
• 1) By Bisphosphonates: Alendronate; Risedronate; Ibandronate; Zoledronic Acid
• 2) By Calcitonin: Salmon Calcitonin; Synthetic Calcitonin Formulations
• 3) By Hormone Therapy: Estrogen Replacement Therapy; Combination Hormone Therapy (Estrogen And Progesterone)

4) By Selective Estrogen Receptor Modulators (SERMs); Raloxifene; Bazedoxifene

• 5) By Parathyroid Hormone-Related Protein (PTHrP) Analog: PTH Analog (Teriparatide); Other PTHrP Analogues
• 6) By Rank Ligand (RANKL) Inhibito: Denosumab
• Companies Mentioned: Pfizer Inc.; F. Hoffmann La Roche Ltd.; Merck and Co Inc.; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Osteoporosis Treatment Market Characteristics

3. Osteoporosis Treatment Market Trends And Strategies

4. Osteoporosis Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Osteoporosis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Osteoporosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Osteoporosis Treatment Market Growth Rate Analysis
• 5.4. Global Osteoporosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Osteoporosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Osteoporosis Treatment Total Addressable Market (TAM)

6. Osteoporosis Treatment Market Segmentation

• 6.1. Global Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bisphosphonates
• Calcitonin
• Hormone Therapy
• Selective Estrogen Receptor Modulators (SERMs)
• Parathyroid Hormone-Related Protein (PTHrP) Analog
• Rank Ligand (RANKL) Inhibitor
• 6.2. Global Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Other Routes
• 6.3. Global Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Retail Pharmacies And Stores
• Online Pharmacies
• 6.4. Global Osteoporosis Treatment Market, Sub-Segmentation Of Bisphosphonates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alendronate
• Risedronate
• Ibandronate
• Zoledronic Acid
• 6.5. Global Osteoporosis Treatment Market, Sub-Segmentation Of Calcitonin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Salmon Calcitonin
• Synthetic Calcitonin Formulations
• 6.6. Global Osteoporosis Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Estrogen Replacement Therapy
• Combination Hormone Therapy (Estrogen And Progesterone)
• 6.7. Global Osteoporosis Treatment Market, Sub-Segmentation Of Selective Estrogen Receptor Modulators (SERMs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Raloxifene
• Bazedoxifene
• 6.8. Global Osteoporosis Treatment Market, Sub-Segmentation Of Parathyroid Hormone-Related Protein (PTHrP) Analog, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PTH Analog (Teriparatide)
• Other PTHrP Analogues
• 6.9. Global Osteoporosis Treatment Market, Sub-Segmentation Of Rank Ligand (RANKL) Inhibito, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Denosumab

7. Osteoporosis Treatment Market Regional And Country Analysis

• 7.1. Global Osteoporosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Osteoporosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Osteoporosis Treatment Market

• 8.1. Asia-Pacific Osteoporosis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Osteoporosis Treatment Market

• 9.1. China Osteoporosis Treatment Market Overview
• 9.2. China Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Osteoporosis Treatment Market

• 10.1. India Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Osteoporosis Treatment Market

• 11.1. Japan Osteoporosis Treatment Market Overview
• 11.2. Japan Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Osteoporosis Treatment Market

• 12.1. Australia Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Osteoporosis Treatment Market

• 13.1. Indonesia Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Osteoporosis Treatment Market

• 14.1. South Korea Osteoporosis Treatment Market Overview
• 14.2. South Korea Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Osteoporosis Treatment Market

• 15.1. Western Europe Osteoporosis Treatment Market Overview
• 15.2. Western Europe Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Osteoporosis Treatment Market

• 16.1. UK Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Osteoporosis Treatment Market

• 17.1. Germany Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Osteoporosis Treatment Market

• 18.1. France Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Osteoporosis Treatment Market

• 19.1. Italy Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Osteoporosis Treatment Market

• 20.1. Spain Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Osteoporosis Treatment Market

• 21.1. Eastern Europe Osteoporosis Treatment Market Overview
• 21.2. Eastern Europe Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Osteoporosis Treatment Market

• 22.1. Russia Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Osteoporosis Treatment Market

• 23.1. North America Osteoporosis Treatment Market Overview
• 23.2. North America Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Osteoporosis Treatment Market

• 24.1. USA Osteoporosis Treatment Market Overview
• 24.2. USA Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Osteoporosis Treatment Market

• 25.1. Canada Osteoporosis Treatment Market Overview
• 25.2. Canada Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Osteoporosis Treatment Market

• 26.1. South America Osteoporosis Treatment Market Overview
• 26.2. South America Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Osteoporosis Treatment Market

• 27.1. Brazil Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Osteoporosis Treatment Market

• 28.1. Middle East Osteoporosis Treatment Market Overview
• 28.2. Middle East Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Osteoporosis Treatment Market

• 29.1. Africa Osteoporosis Treatment Market Overview
• 29.2. Africa Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Osteoporosis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Osteoporosis Treatment Market Competitive Landscape
• 30.2. Osteoporosis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck and Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Osteoporosis Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline Pharmaceutical Ltd.
• 31.2. Takeda Pharmaceutical Company
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. Novo Nordisk A/S
• 31.6. Asahi Kasei Corporation
• 31.7. AstraZeneca Plc.
• 31.8. Viatris Inc.
• 31.9. Teva Pharmaceuticals Industries Ltd.
• 31.10. Daiichi Sankyo Company Ltd
• 31.11. Dr. Reddy's Laboratories
• 31.12. Gedeon Richter Plc.
• 31.13. Celltrion Inc.
• 31.14. Luye Pharma Group
• 31.15. Ligand Pharmaceuticals Incorporated

32. Global Osteoporosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Osteoporosis Treatment Market

34. Recent Developments In The Osteoporosis Treatment Market

35. Osteoporosis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Osteoporosis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Osteoporosis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Osteoporosis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer